Hiv Integrase Inhibitors: The Basis of Effective and Safe Antiretroviral Therapy

Шахгильдян, В. И.

doi:10.21518/2079-701x-2017-4-52-62

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Одним из таких факторов является высокая токсичность препаратов, применяющихся для лечения ВИЧ-инфекции. Спектр потенциальной токсичности АРВП включает в себя нефро-и гепа-тотоксичность, митохондриальные и метаболические эффекты, нарушения со стороны сердечнососудистой системы (ССС) и желудочно-кишечного тракта, психоневрологические нарушения, а также реакции индивидуальной лекарственной чувствительности 3 [3].…”

unclassified

Monitoring the safety of antiretroviral drugs in patients with HIV infection

Матвеев¹,

Крашенинников²,

Егорова³

et al. 2021

VIČ-infekc. immunosupr.

View full text Add to dashboard Cite

The antiretroviral therapy is a lifelong use of a combination of three or more antiretroviral drugs (ARVDs). One of the factors contributing to a significant decrease in patients’ adherence to treatment is the high toxicity of ARVs.The aim of the study is to study the safety of antiretroviral drugs retrospectively and based on spontaneous reports about adverse drug reactions (ADRs) inputted in the ARCADe database.Materials and method. The objects of our research were the 649 spontaneous messages about ARVDs recorded in the regional electronic database (register) of spontaneous messages for period 01 January 2009 — 31 December 2018.Results. Most often, ADR were registered with the use of combined ARVD and non-nucleoside reverse transcriptase inhibitors. Zidovudine and Efavirenz were the leaders in terms of the incidence of ARV ADR. Among the combined anti-HIV drugs, the most frequently ADR were associated with the use of a Lamivudine and Zidovudine combination.Conclusion. Long-term use of ARVs requires regular monitoring of adverse reactions, which will improve the quality of life of patients with HIV infection and significantly increase their compliance with antiretroviral pharmacotherapy.

show abstract

unclassified

Monitoring the safety of antiretroviral drugs in patients with HIV infection

Матвеев¹,

Крашенинников²,

Егорова³

et al. 2021

VIČ-infekc. immunosupr.

View full text Add to dashboard Cite

show abstract

Prevalence and Structure of HIV-1 Drug Resistance to Antiretrovirals in the Volga Federal District in 2008–2019

Peksheva

Kuzovatova

Парфенова

et al. 2022

Viruses

View full text Add to dashboard Cite

The increasing number of HIV-infected people who are receiving ART, including those with low adherence, is causing the spread of HIV drug resistance (DR). A total of 1396 plasma samples obtained from treatment-experienced patients from the Volga federal district (VFD), Russia, were examined to investigate HIV DR occurrence. The time periods 2008–2015 and 2016–2019 were compared. Fragmentary Sanger sequencing was employed to identify HIV resistance to reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) using an ABI 3500XL genetic analyzer, a ViroSeq™ HIV-1 genotyping system (Alameda, CA, USA) and AmpliSense HIV-Resist-Seq reagent kits (Moscow, Russia). In 2016–2019, HIV DR was detected significantly more often than in 2008–2015 (p < 0.01). Mutations to RTIs retained leading positions in the structure of DR. Frequencies of resistance mutations to nucleoside and non-nucleoside RTIs (NRTIs and NNRTIs) in the spectra of detected mutations show no significant differences. Resistance to NRTIs after 2016 began to be registered more often as a part of multidrug resistance (MDR), as opposed to resistance to a single class of antiretrovirals. The frequency of DR mutations to PIs was low, both before and after 2016 (7.9% and 6.1% in the spectrum, respectively, p > 0.05). MDR registration rate became significantly higher from 2008 to 2019 (17.1% to 72.7% of patients, respectively, p < 0.01). M184V was the dominant replacement in all the years of study. A significant increase in the frequency of K65R replacement was revealed. The prevalence of integrase strand transfer inhibitor (INSTI) resistance mutations remains to be investigated.

show abstract

Hiv Integrase Inhibitors: The Basis of Effective and Safe Antiretroviral Therapy

Cited by 2 publications

References 25 publications

Monitoring the safety of antiretroviral drugs in patients with HIV infection

Monitoring the safety of antiretroviral drugs in patients with HIV infection

Prevalence and Structure of HIV-1 Drug Resistance to Antiretrovirals in the Volga Federal District in 2008–2019

Contact Info

Product

Resources

About